alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 12.1

IPC HOLDINGS, LTD. AND SUBSIDIARIES

RATIOS OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED
SHARE DIVIDENDS

Our consolidated ratios of earnings to fixed charges for each of the five fiscal years ended December 31, 2008 and the six months
ended June 30, 2009, are as follows:



|                                                                          |  |                  |         |                         |   |        |  |      |         |      |   |         |      |   |          |   |  |   |        
|------------------------------------------------------------------------- |  | ---------------- | ------- | ----------------------- | - | ------ |  | ---- | ------- | ---- | - | ------- | ---- | - | -------- | - |  | - | -------
|                                                                          |  | Six months ended |         | Year ended December 31,
|                                                                          |  | June 30, 2009    |         | 2008                    |   | 2007   |  | 2006 |         | 2005 |   |         | 2004
|                                                                          |  | ($ in thousands)
|Net income (loss)                                                         |  | $                | 182,127 |                         | $ | 90,447 |  | $    | 385,412 |      | $ | 394,585 |      | $ | (623,399 | ) |  | $ | 138,613
|Preferred share dividends                                                 |  |                  |        |                         |   | 14,339 |  |      | 17,128  |      |   | 17,176  |      |   | 2,644    |   |  |   |       
|Fixed charges                                                             |  |                  |        |                         |   |       |  |      |        |      |   |        |      |   |         |   |  |   |       
|Ratio of earnings to combined fixed charges and preferred share dividends |  |                  |        |                         |   | 6.1: 1 |  |      | 22.5: 1 |      |   | 23.0: 1 |      |   | (1       | ) |  |   |       



|(1) | Earnings for the year ended December 31, 2005 were insufficient to cover combined fixed charges and preferred share dividends by $626.0 million.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------
Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of API Nanotronics Corp. (the Company) on Form
10-KSB for the period ending May 31, 2007, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Phillip DeZwirek, Chief Executive Officer and Treasurer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report
fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/    PHILLIP
DEZWIREKPhillip DeZwirekChief Executive Officer and TreasurerAugust 22, 2007
Daniel Arthur HELEVA, petitioner, v. Michael CLARK, Superintendent, State Correctional Institution at Albion, et al.

No. 18-8535.

Supreme Court of the United States

May 13, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Third Circuit denied.
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 01-7627

DWAYNE ANTHONY CHILDS,

Petitioner - Appellant,

versus

RONALD J. ANGELONE, Director of the Virginia

Department of Corrections,

Respondent - Appellee.

Appeal from the United States District Court for the Eastern

District of Virginia, at Norfolk. Jerome B. Friedman, District

Judge. (CA-00-822-2)

Submitted: May 30, 2002 Decided: June 10, 2002

Before LUTTIG, MICHAEL, and MOTZ, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Roy D. Bradley, BRADLEY LAW FIRM, P.C., Madison, Virginia, for

Appellant. Jerry W. Kilgore, Attorney General of Virginia, Paul G.

Galanides, Assistant Attorney General, Richmond, Virginia, for

Appellee.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
2

PER CURIAM:

Dwayne Anthony Childs appeals the district court’s order

denying relief on his petition filed under 28 U.S.C.A. § 2254 (West

1994 & Supp. 2001). We have reviewed the record and the district

court’s opinion accepting the recommendation of the magistrate

judge and find no reversible error. Accordingly, we deny a

certificate of appealability and dismiss the appeal on the

reasoning of the district court. See Childs v. Angelone, No. CA00-822-2 (E.D. Va. Aug. 23, 2001). We dispense with oral argument

because the facts and legal contentions are adequately presented in

the materials before the court and argument would not aid the

decisional process.

DISMISSED
**Exhibit32**

** **

**CERTIFICATIONS PURSUANT TO 18 U.S.C.SECTION 1350**

 

Inconnection with the Quarterly Report of Titan Pharmaceuticals, Inc. (the“Company”) on Form 10-Q for the period ended June 30, 2004 as filed withthe Securities and Exchange Commission on the date hereof (the “Report”), I,Louis R. Bucalo, M.D., Chairman, President and Chief Executive Officer of theCompany, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuantto section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of myknowledge:

 

(1) The Report fullycomplies with the requirements of section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and

 

(2) The informationcontained in the Report fairly presents, in all material respects, thefinancial condition and result of operations of the Company for the periodcertified.

 

Signed at the City of South San Francisco, in the State of California,this 6th day of August, 2004.

 

 
|   |   | /s/ Louis R. Bucalo   |   |
|--------|--------|-----------------------|--------|
|   |   | Louis R. Bucalo, M.D. |

 

 

Inconnection with the Quarterly Report of Titan Pharmaceuticals, Inc. (the“Company”) on Form 10-Q for the period ended June 30, 2004 as filed withthe Securities and Exchange Commission on the date hereof (the “Report”), I,Robert E. Farrell, J.D., Executive Vice President and Chief Financial Officerof the Company, certify, pursuant to 18 U.S.C. section 1350, as adoptedpursuant to section 906 of the Sarbanes-Oxley Act of 2002, that, to thebest of my knowledge:

 

(1) The Report fullycomplies with the requirements of section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and

 

(2) The informationcontained in the Report fairly presents, in all material respects, thefinancial condition and result of operations of the Company for the periodcertified.

 

Signedat the City of South San Francisco, in the State of California, this 6thday of August, 2004.

 

 
|   | /s/ Robert E. Farrell   |   |
|--------|-------------------------|--------|
|   | Robert E. Farrell, J.D. |

 

----
In Re William KINNEY, et ux., petitioners.

No. 18-1196.

Supreme Court of the United States

May 20, 2019.

Petition for writ of mandamus denied.
# Jornal Oficial C 7/2022

| | ISSN 1977-1010 |
| --- | --- |
| Jornal Oficial
  da União Europeia | C 7 |
| | |
| Edição em língua portuguesa | Comunicações e Informações | 65.° ano7 de janeiro de 2022 |

ISSN 1977-1010

Jornal Oficial

da União Europeia

C 7

Edição em língua portuguesa

Comunicações e Informações

65.° ano7 de janeiro de 2022

---

| Índice | Página |
| --- | --- |
| | IV   Informações |
| | INFORMAÇÕES DAS INSTITUIÇÕES, ÓRGÃOS E ORGANISMOS DA UNIÃO EUROPEIA |
| | Comissão Europeia |
| 2022/C 7/01 | Taxas de câmbio do euro — 6 de janeiro de 2022 | 1 |

Índice

Página

IV   Informações

INFORMAÇÕES DAS INSTITUIÇÕES, ÓRGÃOS E ORGANISMOS DA UNIÃO EUROPEIA

Comissão Europeia

2022/C 7/01

Taxas de câmbio do euro — 6 de janeiro de 2022

1

---

| PT | |
| --- | --- |

PT

---

IV Informações

INFORMAÇÕES DAS INSTITUIÇÕES, ÓRGÃOS E ORGANISMOS DA UNIÃO EUROPEIA

Comissão Europeia

| 7.1.2022 | PT | Jornal Oficial da União Europeia | C 7/1 |
| --- | --- | --- | --- |

7.1.2022

PT

Jornal Oficial da União Europeia

C 7/1

---

Taxas de câmbio do euro (1)

6 de janeiro de 2022

(2022/C 7/01)

1 euro =

| | Moeda | Taxas de câmbio |
| --- | --- | --- |
| USD | dólar dos Estados Unidos | 1,1315 |
| JPY | iene | 131,05 |
| DKK | coroa dinamarquesa | 7,4393 |
| GBP | libra esterlina | 0,83593 |
| SEK | coroa sueca | 10,3265 |
| CHF | franco suíço | 1,0395 |
| ISK | coroa islandesa | 146,80 |
| NOK | coroa norueguesa | 10,0350 |
| BGN | lev | 1,9558 |
| CZK | coroa checa | 24,528 |
| HUF | forint | 359,84 |
| PLN | zlóti | 4,5614 |
| RON | leu romeno | 4,9435 |
| TRY | lira turca | 15,5504 |
| AUD | dólar australiano | 1,5778 |
| CAD | dólar canadiano | 1,4451 |
| HKD | dólar de Hong Kong | 8,8272 |
| NZD | dólar neozelandês | 1,6752 |
| SGD | dólar singapurense | 1,5388 |
| KRW | won sul-coreano | 1 362,06 |
| ZAR | rand | 17,7932 |
| CNY | iuane | 7,2187 |
| HRK | kuna | 7,5197 |
| IDR | rupia indonésia | 16 291,88 |
| MYR | ringgit | 4,7670 |
| PHP | peso filipino | 57,943 |
| RUB | rublo | 86,5088 |
| THB | baht | 37,962 |
| BRL | real | 6,4420 |
| MXN | peso mexicano | 23,2549 |
| INR | rupia indiana | 84,2475 |

Moeda

Taxas de câmbio

USD

dólar dos Estados Unidos

1,1315

JPY

iene

131,05

DKK

coroa dinamarquesa

7,4393

GBP

libra esterlina

0,83593

SEK

coroa sueca

10,3265

CHF

franco suíço

1,0395

ISK

coroa islandesa

146,80

NOK

coroa norueguesa

10,0350

BGN

lev

1,9558

CZK

coroa checa

24,528

HUF

forint

359,84

PLN

zlóti

4,5614

RON

leu romeno

4,9435

TRY

lira turca

15,5504

AUD

dólar australiano

1,5778

CAD

dólar canadiano

1,4451

HKD

dólar de Hong Kong

8,8272

NZD

dólar neozelandês

1,6752

SGD

dólar singapurense

1,5388

KRW

won sul-coreano

1 362,06

ZAR

rand

17,7932

CNY

iuane

7,2187

HRK

kuna

7,5197

IDR

rupia indonésia

16 291,88

MYR

ringgit

4,7670

PHP

peso filipino

57,943

RUB

rublo

86,5088

THB

baht

37,962

BRL

real

6,4420

MXN

peso mexicano

23,2549

INR

rupia indiana

84,2475

---

(1)  Fonte: Taxas de câmbio de referência publicadas pelo Banco Central Europeu.

---
CONSENT OF INDEPENDENT AUDITORS

We consent to the incorporation of our report dated March 18, 2004, on the
financial statements of Centrex, Inc. (the "Company") at December 31, 2003, for
the period from inception (October 6, 1998) to December 31, 2003, and for the
years ended December 31, 2003 and 2002, included in this Form 10-KSB Annual
Report of Centrex, Inc. as of December 31, 2003, into the Company's Registration
Statements on Form S-8 (File numbers 333-98957, 333-73972, 333-65448,
333-104316, 333-107398, 333-108758, and 333-110400) and the Company's
Registration Statement on Form SB-2 (File number 333-101593) and Form SB-2MEF
(File number 333-102646).

Our report, dated March 18, 2004, contains an explanatory paragraph that states
that Centrex, Inc. is a development stage company with insufficient revenues to
fund development and operating expenses, which raises substantial doubt about
its ability to continue as a going concern. The financial statements do not
include any adjustments that might result from the outcome of that uncertainty.


TULLIUS TAYLOR SARTAIN & SARTAIN LLP

Tulsa, Oklahoma
March 29, 2004
<PAGE>


                                                                     Exhibit 8.1

                               LIST OF SIGNIFICANT SUBSIDIARIES

                                            PLACE OF           OWNERSHIP
                   COMPANY                INCORPORATION        INTEREST
       -----------------------------   -----------------     -------------
       Delta Galil USA. Inc.            Delaware, U.S.A.         100%

       Delta Galil Europe Ltd.          U.K.                     100%

       Delta Galil Holland B.V.         Holland                  100%

       Delta Textile Egypt  -           Egypt                    100%
       Free Zone S.A.E.

       Century Wear Corporation (WLL)   Jordan                    50%(1)

       Dominion Hosiery Inc.            Canada                   100%

       Delta Galil Hungary KFT          Hungary                  100%

       Delta Textile Marketing Ltd.     Israel                   100%

       Delta Textile (New York) Ltd.    New York, U.S.A.         100%

       Delta Elastic Tapes              Israel                    90%
       Industries, Ltd.


-----------------------
(1) Delta Galil effectively controls this joint venture as a result of holding
an additional controlling share.
[Federal Register Volume 87, Number 93 (Friday, May 13, 2022)]
[Notices]
[Page 29381]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-10240]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Subcutaneous Drug Development & Delivery 
Consortium, Inc.

    Notice is hereby given that, on April 25, 2022, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Subcutaneous Drug Development & 
Delivery Consortium, Inc. (``Subcutaneous Drug Development & Delivery 
Consortium, Inc.'') has filed written notifications simultaneously with 
the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. 
Specifically, Roche Holding AG, Basel, SWITZERLAND, has been added as a 
party to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and Subcutaneous Drug Development & 
Delivery Consortium, Inc. intends to file additional written 
notifications disclosing all changes in membership.
    On October 26, 2020, Subcutaneous Drug Development & Delivery 
Consortium, Inc. filed its original notification pursuant to Section 
6(a) of the Act. The Department of Justice published a notice in the 
Federal Register pursuant to Section 6(b) of the Act on December 3, 
2020 (85 FR 78148).
    The last notification was filed with the Department on December 8, 
2021. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on January 13, 2022 (87 FR 2182).

Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2022-10240 Filed 5-12-22; 8:45 am]
BILLING CODE 4410-11-P
Mark ELLIOT, petitioner, v. Carmen Denise PALMER, Warden.

No. 18-5453.

Supreme Court of the United States

May 13, 2019.

Petition for rehearing denied.
```
 
 
IN DELIVERY MONTH EUA - GREEN EXCHANGE                               Code-006GEC
OPTION AND FUTURES COMBINED POSITIONS AS OF 11/15/11          |
--------------------------------------------------------------| NONREPORTABLE
      NON-COMMERCIAL      |   COMMERCIAL    |      TOTAL      |   POSITIONS
--------------------------|-----------------|-----------------|-----------------
  Long  | Short  |Spreads |  Long  | Short  |  Long  | Short  |  Long  | Short
--------------------------------------------------------------------------------
(CONTRACTS OF 1000 EUA)                              OPEN INTEREST:       73,136
COMMITMENTS
   1,027    2,036   10,944   60,845   59,866   72,816   72,846      320      290

CHANGES FROM 11/08/11 (CHANGE IN OPEN INTEREST:       -436)
     181       50     -273     -584     -453     -676     -676      240      240

PERCENT OF OPEN INTEREST FOR EACH CATEGORY OF TRADER
     1.4      2.8     15.0     83.2     81.9     99.6     99.6      0.4      0.4

NUMBER OF TRADERS IN EACH CATEGORY (TOTAL TRADERS:       21)
       3        5        5        7       11       12       20
```

----

Updated November 18, 2011
<TABLE> <S> <C>

<ARTICLE> 7
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<DEBT-HELD-FOR-SALE>                           149,324
<DEBT-CARRYING-VALUE>                                0
<DEBT-MARKET-VALUE>                                  0
<EQUITIES>                                      28,585
<MORTGAGE>                                           0
<REAL-ESTATE>                                        0
<TOTAL-INVEST>                                 177,909
<CASH>                                           8,585
<RECOVER-REINSURE>                               1,180
<DEFERRED-ACQUISITION>                           9,862
<TOTAL-ASSETS>                                 234,237
<POLICY-LOSSES>                                102,071
<UNEARNED-PREMIUMS>                             35,153
<POLICY-OTHER>                                       0
<POLICY-HOLDER-FUNDS>                                0
<NOTES-PAYABLE>                                      0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        41,903
<OTHER-SE>                                      45,489
<TOTAL-LIABILITY-AND-EQUITY>                   234,237
<PREMIUMS>                                      22,388
<INVESTMENT-INCOME>                              2,211
<INVESTMENT-GAINS>                                  28
<OTHER-INCOME>                                      57
<BENEFITS>                                      12,481
<UNDERWRITING-AMORTIZATION>                      6,946
<UNDERWRITING-OTHER>                               523
<INCOME-PRETAX>                                  4,734
<INCOME-TAX>                                     1,112
<INCOME-CONTINUING>                              3,622
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     3,622
<EPS-PRIMARY>                                     0.49
<EPS-DILUTED>                                     0.49
<RESERVE-OPEN>                                  85,723<F1>
<PROVISION-CURRENT>                             12,481
<PROVISION-PRIOR>                                    0
<PAYMENTS-CURRENT>                               1,196
<PAYMENTS-PRIOR>                                 6,073
<RESERVE-CLOSE>                                 90,935<F1>
<CUMULATIVE-DEFICIENCY>                              0
<FN>
<F1>UNPAID LOSS AND LOSS ADJUSTMENT EXPENSES DIFFER FROM THE AMOUNTS REPORTED IN
THE CONSOLIDATED FINANCIAL STATEMENTS BECAUSE OF THE INCLUSION HEREIN OF
REINSURANCE RECEIVABLES OF $11,136 AND $10,919 AT MARCH 31, 1997 AND DECEMBER
31, 1996, RESPECTIVELY.
</FN>
        

</TABLE>
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 05-6998
UNITED STATES OF AMERICA, Plaintiff - Appellee, versus PATRICK LAMAR HARRIS, Defendant - Appellant. Appeal from the United States District Court for the District of South Carolina, at Florence. C. Weston Houck, Senior District Judge. (CR-94-297) Submitted: April 27, 2006 Decided: May 3, 2006 Before NIEMEYER and MOTZ, Circuit Judges, and HAMILTON, Senior Circuit Judge. Affirmed by unpublished per curiam opinion. Patrick Lamar Harris, Appellant Pro Se. Marshall Prince, OFFICE OF THE UNITED STATES ATTORNEY, Columbia, South Carolina, for Appellee. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).- 2 - PER CURIAM: Patrick Lamar Harris appeals from the district court’s orders denying his 18 U.S.C. § 3582(c)(2) (2000) motion for reduction of sentence and denying his motion for reconsideration. Harris asserts that he is entitled to a reduction of sentence based on Amendment 591 to the U.S. Sentencing Guidelines. This Amendment requires a sentencing court to apply the offense guideline referenced in the Statutory Index in Appendix A based on the statute of conviction, rather than a defendant’s actual conduct. See U.S. Sentencing Guidelines Manual App. C, Amend. 591 (2004); United States v. Rivera , 293 F.3d 584, 586-87 (2d Cir. 2002). Because Harris was sentenced under the correct guideline for his convicted offenses, we affirm the orders of the district court. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

AFFIRMED
Sheila L. GAINES, petitioner, v. Nancy A. BERRYHILL, Acting Commissioner of Social Security.

No. 18-5421.

Supreme Court of the United States

Oct. 1, 2018.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.
EXHIBIT 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Annual Report of Aquatic Cellulose International
Corporation (the "Company") on Form 10KSB for the period ending May 31, 2002 as
filed with the Securities and Exchange Commission on the date hereof (the
"Report"), I, Sheridan Westgarde, Chief Financial Officer of the Company,
certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the
Sarbanes-Oxley Act of 2002, that to the best of the undersigned's knowledge and
belief:

     (1)  The Report fully complies with the requirements of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and result of operations of
          the Company.




                                                /s/  Sheridan Westgarde
                                                ------------------------------
                                                Sheridan Westgarde
                                                Chief Financial Officer
                                                February 27, 2004
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr., Chief Justice

Michael F. Cavanagh

Stephen J. Markman

Mary Beth Kelly

Brian K. Zahra

Bridget M. McCormack

David F. Viviano, Justices

I, Larry S. Royster, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

 December 2, 2013

Order 

Clerk

December 2, 2013

148010 & (30)

VIRGINIA CHAMBERLAIN and

LEEZARD INVESTMENTS, LLC,

Plaintiffs-Appellees,

SC: 148010

v COA: 311090

Kent CC: 09-007287-CK

BILL MESSER, MESSER ORTHOPEDICSROCKFORD, LLC, MESSER ORTHOPEDICSPLAINFIELD, LLC, and RESSEM, LLC, d/b/a 

MESSER MOBILITY DETROIT,

Defendants, 

and 

FREDDY E. SACKLLAH,

Appellant.

________________________________________/

On order of the Chief Justice, the stipulation to dismiss the application for leave to 

appeal is GRANTED. The dismissal is with prejudice and without costs or fees to either 

party.